RxDoctor Payments Data

Virginia Glockzin, PA

Physician Assistant · Greenville, NCNPI 1497480024

Payments from drug & device makers

$3,182in general payments, 2019–2025

Across 100 payments — averaging $31.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$433
  • Xeris Pharmaceuticals, Inc.$304
  • Amgen$286
  • Novo Nordisk$283
  • Sequel Med Tech, LLC$252
  • Medtronic$233
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,182100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,182 in reported general payments places this provider in the 85th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$214,479
Medicare patients
212
Services billed
17,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide382$417,118
MounjaroTirzepatide166$176,744
Tresiba Flextouch U-100Insulin Degludec66$62,128
JardianceEmpagliflozin47$55,526
TrulicityDulaglutide47$46,522
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/733$39,627
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog45$38,767
Evenity (2 Syringes)Romosozumab-Aqqg15$36,610
TymlosAbaloparatide13$36,170
RybelsusSemaglutide32$35,090
FarxigaDapagliflozin Propanediol43$32,063
Soliqua 100-33Insulin Glargine/Lixisenatide14$16,190
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$13,398
Tresiba Flextouch U-200Insulin Degludec19$13,264
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$10,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$283$456,367428 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$433$225,999225 claims
AmgenEvenity (2 Syringes)$286$36,61015 claims
Radius Health, Inc.Tymlos$61$36,17013 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$16$16,19014 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$78$64268 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →